78,101 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Bought by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund purchased a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 78,101 shares of the biopharmaceutical company's stock, valued at approximately $2,351,000. Illinois Municipal Retirement Fund owned about 0.05% of TG Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Blue Trust Inc. lifted its stake in TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock valued at $35,000 after buying an additional 849 shares during the last quarter. Synergy Asset Management LLC acquired a new position in TG Therapeutics during the 4th quarter valued at about $75,000. GAMMA Investing LLC increased its stake in shares of TG Therapeutics by 562.4% in the fourth quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company's stock valued at $77,000 after purchasing an additional 2,171 shares during the period. KBC Group NV raised its holdings in shares of TG Therapeutics by 30.5% during the third quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company's stock valued at $109,000 after buying an additional 1,092 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd bought a new position in TG Therapeutics in the 3rd quarter worth approximately $111,000. 58.58% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have commented on TGTX. The Goldman Sachs Group raised their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. StockNews.com cut TG Therapeutics from a "hold" rating to a "sell" rating in a report on Friday, January 31st. HC Wainwright reaffirmed a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a research note on Wednesday, January 15th. Finally, JPMorgan Chase & Co. upped their price objective on TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a report on Monday, November 25th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, TG Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $40.67.

Insider Activity

In related news, CFO Sean A. Power sold 10,021 shares of the firm's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the transaction, the chief financial officer now owns 660,611 shares of the company's stock, valued at approximately $18,847,231.83. This trade represents a 1.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 10.50% of the stock is owned by company insiders.

TG Therapeutics Price Performance

Shares of TGTX traded up $4.33 during trading hours on Monday, hitting $34.42. 12,628,827 shares of the company were exchanged, compared to its average volume of 2,402,081. The firm has a fifty day simple moving average of $30.75 and a 200-day simple moving average of $28.14. The company has a market capitalization of $5.36 billion, a PE ratio of -344.17 and a beta of 2.26. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. TG Therapeutics, Inc. has a one year low of $12.93 and a one year high of $36.84.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.06. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. As a group, sell-side analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.